References
- International Diabetes Federation. IDF diabetes atlas. 7. Brussels: International Diabetes Federation; 2015.
- Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64-S71.
- Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-6
- Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-72.
- Huang Z, Luo X, Liu M, Chen L. Function and regulation of apelin. APJ system in digestive physiology and pathology. J Cell Physiol. 2019;234:7796-810.
- Roche J, Rame C, Reverchon M, Mellouk N, Cornuau M, Guerif F, et al. Apelin (APLN) and Apelin Receptor (APLNR) in human ovary: expression, signaling, and regulation of steroidogenesis in primary human luteinized granulosa cells. Biol Reprod. 2016;95:104.
- Liu W, Yan J, Pan W, Tang M. Apelin/Elabela-APJ: anovel therapeutic target in the cardiovascular system. Ann Transl Med. 2020;8(5):243.
- Wan T, Fu M, Jiang Y, Jiang W, Li P, Zhou S. Research progress on mechanism of neuroprotective roles of Apelin-13 in Prevention and Treatment of Alzheimer’s Disease. Neurochem Res. 2021;47(2):205-17.
- Zhou JX, Shuai NN, Wang B, Jin X, Kuang X, Tian SW. Neuroprotective gain of Apelin/APJ system. Neuropeptides. 2021;87: 102131.
- Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, et al. Plasma Apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes. 2007;115(7):428-32.
- Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, et al. LDL-cholesterol lowering increases plasma Apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204(1):222-8.
- Patlak M. New weapons to combat an ancient disease: treating diabetes. FASEB J. 2002;16(14):1853.
- Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK (eds). Robbins and Cotran Pathologic basis of disease (7th ed).Philadelphia: Saunders; 2005:1156-226.
- Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228-36.
- Genetic basis of type 1 and type 2 diabetes, obesity, and their complications. Advances and emerging opportunities in diabetes research: a Strategic Planning report of the DMICC. [www.niddk.nih.gov/NR] (access 22 December 2011).
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, TreacherFF, Turner RC.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
- Kartal H, Comu FM, Kucuk A, Polat Y, Dursun AD, Arslan M. Effect of Apelin-13 on erythrocyte deformability during ischaemiareperfusion injury of heart in diabetic rats. Bratisl Lek Listy. 2017;118(3):133-6
- Du JH, Li X, Li R, Xu L, Ma RR, Liu SF, et al. Elevation of serum Apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients. Int J Ophthalmol. 2014;7(6):968-73.
- Chen H, Li J, Jiao L, Petersen RB, Li J, Peng A, et al. Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse. J Physiol. 2014;592(3):505-21.
- Castan-Laurell I, Masri B, Valet P. The apelin/APJ system as a therapeutic target in metabolic diseases. Expert Opin Ther Targets. 2019;23:215-25
- Sawane M, Kajiya K, Kidoya H, Takagi M, Muramatsu F, Takakura N. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes. 2013;62:1970-80
- Hu H, He L, Li L, Chen L. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab. 2016;119:20-7
- Palmer ES, Nigel I, O’Harte FPM.Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An Update. Clin Med Insights Endocrinol Diabetes. 2022;15:11795514221074679.
- Duparc T, Colom A, Cani PD, Massaly N, Rastrelli S, Drougard A, et al. Central apelin controls glucose homeostasisviaa nitric oxide-dependent pathway in mice. Antioxid Redox Signal. 2011;15:1477-96.
- Han S, Englander EW, Gomez GA, Rastellini C, Quertermous T, Kundu RK, et al. Pancreatic islet APJ deletion reduces islet density and glucose tolerance in mice. Endocrinology. 2015;156:2451-60.
- Zhang BH, Wang W, Wang H, YinJ, Zeng XJ. Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One. 2013;8(4):e60457.
- Dawood A, Abdelraof M, El Ghobashy Y. The relationship between serum apelin level and different grades of diabetic nephropathy in type 2 diabetic patients. Egypt J Obes Diabetes Endocrinol. 2017;3(1):32.
- Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol. 2013;304: F788-F800.